# Susan Silbermann

> Da stagista Pfizer a Global President: 34 anni nella vaccine enterprise globale

## Dati Essenziali

| Aspetto | Dettaglio |
|---------|-----------|
| **Nazionalita'** | USA |
| **Formazione** | BS Tufts, MBA/MA NYU Stern |
| **Ruolo attuale** | Independent Corporate Board Member |
| **Carriera principale** | Pfizer, 34 anni (1988-2021) |

---

## Formazione

| Periodo | Istituzione | Dettaglio |
|---------|-------------|-----------|
| - | [Tufts University](../university/tufts.md) | BS Biology and French |
| - | [NYU Stern School of Business](../university/nyu.md) | Joint MBA/MA Business Administration and French Political and Social Studies (con Institute of French Studies) |

**Note**: Background insolito per pharma executive: biologia combinata con studi francesi e poi MBA. Profilo internazionale fin dalla formazione.

---

## Carriera e Ruoli

### Timeline Professionale

| Periodo | Ruolo | Organizzazione |
|---------|-------|----------------|
| **1988** | Summer Intern, US Marketing Division | [Pfizer](../pharma/pfizer.md) |
| **1992** | International Pharmaceuticals Group | [Pfizer](../pharma/pfizer.md) |
| **1988-2021** | Carriera progressiva (34 anni) | [Pfizer](../pharma/pfizer.md) |
| **2012-2018** | First Global President, Pfizer Vaccines | [Pfizer](../pharma/pfizer.md) |
| **2018-2021** | Global President, Emerging Markets | [Pfizer](../pharma/pfizer.md) |
| **2020-2021** | Chair, Pfizer Global COVID-19 Task Force | [Pfizer](../pharma/pfizer.md) |
| **2017-2020** | Board Member (IFPMA representative) | [Gavi](../agency/gavi.md) |
| **2021-** | Board of Directors | [LianBio](../pharma/lianbio.md) |
| **2022-** | Board of Directors | [IAVI](../agency/iavi.md) |
| **2022-** | Board of Directors | [Mallinckrodt](../pharma/mallinckrodt.md) |
| - | Board of Directors | [HilleVax](../pharma/hillevax.md) |

### Pfizer (1988-2021)

Carriera di 34 anni iniziata come stagista estiva:

**Fasi principali:**
- **1988**: Ingresso come intern, US Marketing Division
- **1992**: Passaggio all'International Pharmaceuticals Group
- **Ruoli intermedi**: Marketing, commercial development, general management in USA e mercati internazionali
- **2012-2018**: Prima Global President di Pfizer Vaccines - espansione da un prodotto a portafoglio multiplo, da sviluppo interno a sourcing esterno
- **2018-2021**: Global President Emerging Markets - 10.000 colleghi in 100+ paesi, incluso business vaccini
- **2020-2021**: Chair COVID-19 Task Force - supervisione sicurezza e continuita' operativa per 100.000 dipendenti in 100+ paesi
- Champion di diversita', equita' e inclusione

### Governance Post-Pfizer

Portfolio di board multipli costruito dopo il ritiro da Pfizer (2021):

| Board | Tipo | Dal |
|-------|------|-----|
| [IAVI](../agency/iavi.md) | Non-profit (HIV/TB vaccines) | 2022 |
| [LianBio](../pharma/lianbio.md) | Biotech (China-focused) | 2021 |
| [Mallinckrodt](../pharma/mallinckrodt.md) | Pharma (specialty) | 2022 |
| [HilleVax](../pharma/hillevax.md) | Biotech (norovirus vaccine) | - |
| Meet the Writers | Non-profit (education) | - |

### Board Precedenti

| Board | Tipo |
|-------|------|
| [Gavi](../agency/gavi.md) | Vaccine alliance (2017-2020) |
| [Catalyst](../foundation/catalyst.md) | Non-profit (women in business) |
| [Johns Hopkins](../university/johns-hopkins.md) | Carey School of Business Board |
| [Harvard](../university/harvard.md) | Kennedy School Women's Leadership Board; Defeating Malaria Initiative |

---

## Rete di Connessioni

### Mappa delle Appartenenze

```
                   SUSAN SILBERMANN
                         |
     +-------------------+-------------------+
     |                   |                   |
     v                   v                   v
   PFIZER            GOVERNANCE         GLOBAL HEALTH
  (34 anni)          (post-2021)           (boards)
     |                   |                   |
  Intern 1988      HilleVax             IAVI (2022-)
  VP Vaccines      LianBio              Gavi (2017-20)
  GP Emerging      Mallinckrodt
  COVID Chair
     |                   |
     +-------------------+
                |
                v
          GOVERNMENT
     VP Advisory Council
     Doing Business Africa
```

### Network Professionale

| Nome | Connessione |
|------|-------------|
| [Mark Feinberg](mark-feinberg.md) | CEO IAVI (Silbermann nel board) |
| [Eric Goosby](eric-goosby.md) | Chair IAVI Board (collega board) |
| [Rajeev Venkayya](rajeev-venkayya.md) | Board IAVI (collega board) |
| [Albert Bourla](albert-bourla.md) | CEO Pfizer (collega, Silbermann senior executive) |
| [Seth Berkley](seth-berkley.md) | CEO Gavi durante mandato board Silbermann (2017-2020) |

---

## Potere Esercitato

### Pfizer Vaccines Global Architecture

| Aspetto | Dettaglio |
|---------|-----------|
| **First Global President Vaccines** | Creazione della struttura globale vaccini Pfizer |
| **Portfolio expansion** | Da un prodotto a portafoglio multiplo |
| **Sourcing model** | Da sviluppo interno a licensing esterno |
| **Emerging Markets** | 10.000 colleghi, 100+ paesi |
| **COVID Task Force** | 100.000 dipendenti, continuita' operativa globale |

### Pattern di carriera

| Fase | Caratteristica |
|------|----------------|
| **Intern → President** | 34 anni nello stesso gruppo, crescita organica |
| **International focus** | Ruoli su tre continenti, expertise mercati emergenti |
| **Vaccines pioneer** | Prima presidente globale vaccini Pfizer |
| **COVID response** | Chair task force durante pandemia |
| **Governance portfolio** | Post-ritiro: board pharma + global health |

### Ruolo Gavi

Come board member Gavi rappresentando IFPMA (2017-2020), ponte diretto tra industria farmaceutica e vaccine alliance globale. Periodo che include la preparazione alla risposta COVID-19.

---

## Connessioni PowerLink

### Organizzazioni

| Entita' | Connessione |
|---------|-------------|
| [Pfizer](../pharma/pfizer.md) | Executive 34 anni (1988-2021), Global President Vaccines e Emerging Markets |
| [IAVI](../agency/iavi.md) | Board of Directors dal 2022 |
| [Gavi](../agency/gavi.md) | Board (IFPMA) 2017-2020 |
| [Governo USA](../government/governo-usa.md) | Vice Chair, President's Advisory Council on Doing Business in Africa |
| [HilleVax](../pharma/hillevax.md) | Board |
| [LianBio](../pharma/lianbio.md) | Board dal 2021 |
| [Mallinckrodt](../pharma/mallinckrodt.md) | Board dal 2022 |
| [Catalyst](../foundation/catalyst.md) | Board |
| [Johns Hopkins](../university/johns-hopkins.md) | Carey Business School Board |
| [Harvard](../university/harvard.md) | Kennedy School Women's Leadership Board; Defeating Malaria |
| [Tufts](../university/tufts.md) | BS Biology and French |
| [NYU](../university/nyu.md) | MBA/MA Stern and Institute of French Studies |

### Persone

| Persona | Relazione |
|---------|-----------|
| [Mark Feinberg](mark-feinberg.md) | CEO IAVI |
| [Eric Goosby](eric-goosby.md) | Chair IAVI Board |
| [Albert Bourla](albert-bourla.md) | CEO Pfizer |
| [Seth Berkley](seth-berkley.md) | CEO Gavi (durante board 2017-20) |

---

## Timeline

| Anno | Evento |
|------|--------|
| - | BS Biology and French, Tufts University |
| - | MBA/MA, NYU Stern / Institute of French Studies |
| **1988** | Ingresso Pfizer come summer intern |
| **1992** | Passaggio International Pharmaceuticals Group |
| **2012** | Prima Global President, Pfizer Vaccines |
| **2017** | Entra board Gavi (rappresentante IFPMA) |
| **2018** | Global President, Pfizer Emerging Markets |
| **2020** | Chair Pfizer Global COVID-19 Task Force; lascia board Gavi |
| **2021** | Ritiro da Pfizer dopo 34 anni; entra board LianBio |
| **2022** | Entra board IAVI, Mallinckrodt, HilleVax |

---

## Pattern rilevanti

**Intern-to-President**: Caso raro di carriera interamente costruita dentro una singola corporation (34 anni), da stagista a Global President. Fedelta' aziendale estrema.

**Pfizer Vaccines architect**: Come prima Global President Pfizer Vaccines, ha costruito l'infrastruttura che poi ha prodotto il vaccino COVID-19 (BNT162b2/Comirnaty). La struttura di sourcing esterno che ha creato e' quella che ha permesso la partnership con BioNTech.

**IFPMA → Gavi pipeline**: Rappresentante dell'industria pharma nel board dell'alleanza vaccinale globale. Ponte diretto tra interessi commerciali e distribuzione pubblica.

**Post-retirement board portfolio**: Pattern classico di ex-executive pharma che accumula board seats in biotech (HilleVax, LianBio, Mallinckrodt) e global health (IAVI). Monetizzazione del network e dell'expertise.

**IAVI Big Pharma contingent**: Con Feinberg (ex-Merck), Venkayya (ex-Takeda), Blumberg (Teva), Silbermann completa il quartetto pharma nel board IAVI.

---

## Fonti

### Biografie
- [IAVI - Susan Silbermann](https://www.iavi.org/person/susan-silbermann/)
- [Gavi - Board Member](https://www.gavi.org/our-alliance/governance/gavi-board/board-members/susan-silbermann)
- [WomenLift Health](https://www.womenlifthealth.org/profile/susan-silbermann/)
- [AS/COA Speaker](https://www.as-coa.org/speakers/susan-silbermann)
- [Aspen Ideas](https://www.aspenideas.org/speakers/susan-silbermann)

### Nomine
- [IAVI Board Appointment (Feb 2022)](https://www.iavi.org/press-release/iavi-appoints-three-notable-global-health-and-business-leaders-to-its-board-of-directors/)
- [LianBio Board Appointment (Oct 2021)](https://www.businesswire.com/news/home/20211012005341/en/LianBio-Appoints-Susan-Silbermann-to-Board-of-Directors)
- [Mallinckrodt Board Appointment (Oct 2022)](https://www.prnewswire.com/news-releases/mallinckrodt-announces-appointment-of-susan-silbermann-to-its-board-of-directors-301642185.html)

---

*Ultimo aggiornamento: Febbraio 2026*
